ELAN vs PATH · rev $4.44B vs P/E 19, rev $1.61B
Elanco Animal Health (ELAN) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Elanco Animal Health (ELAN) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ELAN revenue for 2024-12-31 was $4.44B. Net income was $338.0M. Revenue was up 0.5% from 2023-12-31 to 2024-12-31. ELAN currently screens at market cap $11.80B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ELAN currently screens at market cap $11.80B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ELAN and PATH stock pages for the full models.
Not investment advice.